Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.32 |
| ▸ | TSHR | P16473 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.30 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.30 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28412324 | 0.93 | MEN1 (0.33) | ELANEDAGLADAGLB | |
| SCHEMBL28412323 | 0.93 | MEN1 (0.33) | ELANEDAGLADAGLB | |
| SCHEMBL20899977 | 0.91 | HCRTR1 (0.33) | CYP3A4TSHRALDH1A1HCRTR1DAGLA | |
| SCHEMBL20899976 | 0.91 | HCRTR1 (0.33) | CYP3A4TSHRALDH1A1HCRTR1DAGLA | |
| SCHEMBL20900087 | 0.85 | MEN1 (0.34) | HCRTR1ELANEDAGLADAGLB | |
| SCHEMBL20900090 | 0.85 | MEN1 (0.34) | HCRTR1ELANEDAGLADAGLB | |
| SCHEMBL29640239 | 0.83 | TRPV1 (0.38) | KCNH2 | |
| SCHEMBL28407464 | 0.83 | TRPV1 (0.38) | KCNH2 | |
| SCHEMBL20908059 | 0.81 | CTSS (0.34) | ELANEATMPOLB | |
| SCHEMBL28407522 | 0.81 | CTSS (0.34) | ELANEATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352329-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | CYP3A4 922/4885TSHR 4797/4885ALDH1A1 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.